A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
Daniel A. Goldstein(Rabin Medical Center), Alona Zer(Rambam Health Care Campus), Noa Gordon(Ben-Gurion University of the Negev), Conor Steuer(Emory University), Nikita Patel(Emory University), Salomon M. Stemmer(Tel Aviv University), Michal Davidescu(Clalit Health Services), Moshe Leshno(Tel Aviv University)
Cited by 102
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis
|Cell|2019|446